Table 3.

Time series analysis describing the trends in the evolution of the proportion of patients with NVAF treated with anticoagulants, aspirin or other AP therapy alone or without any antithrombotic treatment from April 2012 to April 2015 in the UK by time since NVAF diagnosis

	Pre-ESC*			Post-ESC†			Post-NICE†
	β	SE	p Value	β	SE	p Value	β	SE	p Value
A. Anticoagulation treatment
Diagnosed <12 months
Level	43.09	0.26	<0.0001	0.28	0.35	0.418	0.10	0.49	0.846
Trend	0.34	0.02	<0.0001	0.26	0.03	<0.0001	0.12	0.09	0.171
Diagnosed ≥12 months
Level	49.01	0.07	<0.0001	0.00	0.10	0.981	−0.16	0.14	0.251
Trend	0.13	0.01	<0.0001	0.18	0.01	<0.0001	0.15	0.02	<0.0001
B. Aspirin (ASA) or other AP only
Diagnosed <12 months
Level	41.94	0.24	<0.0001	−0.20	0.31	0.518	−0.63	0.44	0.159
Trend	−0.36	0.02	<0.0001	−0.26	0.03	<0.0001	−0.10	0.08	0.226
Diagnosed ≥12 months
Level	35.05	0.06	<0.0001	0.03	0.08	0.737	−0.33	0.12	0.008
Trend	−0.12	0.01	<0.0001	−0.15	0.01	<0.0001	−0.21	0.02	<0.0001
C. Without any antithrombotic treatment
Diagnosed <12 months
Level	14.97	0.15	<0.0001	−0.08	0.19	0.6835	0.54	0.27	0.057
Trend	0.02	0.01	0.211	0.00	0.02	0.9262	−0.03	0.05	0.612
Diagnosed ≥12 months
Level	15.94	0.07	<0.0001	−0.03	0.10	0.789	0.49	0.14	0.001
Trend	−0.01	0.01	0.174	−0.03	0.01	0.000	0.06	0.02	0.015

*Pre-ESC data are base level, base trend.

†Post-ESC and post-NICE data are change in level, change in trend.

AP, antiplatelet; ESC, European Society of Cardiology; NICE, National Institute for Health and Care Excellence; NVAF, non-valvular atrial fibrillation.